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Abstract
Background—Malignant glioma (MG), the most common primary brain tumor in adults, is 
extremely aggressive and uniformly fatal. Several treatment strategies have shown significant 
preclinical promise in murine models of glioma; however, none have produced meaningful clinical 
responses in human patients. We hypothesize that introduction of an additional preclinical animal 
model better approximating the complexity of human MG, particularly in interactions with host 
immune responses; will bridge the existing gap between these two stages of testing. Here, we 
characterize the immunologic landscape and gene expression profiles of spontaneous canine 
glioma and evaluate its potential for serving as such a translational model.
Methods—RNA in situ hybridization, flowcytometry, and RNA sequencing were used to 
evaluate immune cell presence and gene expression in healthy and glioma-bearing canines.
Results—Similar to human MGs, canine gliomas demonstrated increased intratumoral immune 
cell infiltration (CD4+, CD8+ and CD4+Foxp3+ T-cells). The peripheral blood of glioma-bearing 
dogs also contained a relatively greater proportion of CD4+Foxp3+ regulatory T-cells and 
plasmacytoid dendritic cells. Tumors were strongly positive for PD-L1 expression and glioma-
bearing animals also possessed a greater proportion of immune cells expressing the immune 
checkpoint receptors CTLA-4 and PD-1. Analysis of differentially expressed genes in our canine 
populations revealed several genetic changes paralleling those known to occur in human disease.
Conclusion—Naturally occurring canine glioma has many characteristics closely resembling 
human disease, particularly with respect to genetic dysregulation and host immune responses to 
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tumors, supporting its use as a translational model in the preclinical testing of prospective anti-
glioma therapies proven successful in murine studies.
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INTRODUCTION
Malignant gliomas (MGs) are the most frequently diagnosed, and most lethal, primary brain 
tumors in adults. With an extremely poor prognosis and near 100% recurrence rate, these 
tumors remain one of the biggest therapeutic challenges of the modern era.1,2 A variety of 
immunotherapy-based regimens have shown significant antitumor efficacy in preclinical 
evaluations, with some resulting in complete and sustained tumor eradication in murine 
models of glioma.3–5 However none have come close to challenging the current standard of 
care for human patients suffering from this devastating illness. Additionally, toxicities 
initially encountered in human phase I/II trials are often not initially identified in preclinical 
mouse studies. Although the murine model remains an effective, economical, and vital 
preclinical model for performing initial molecular studies to understand this disease process, 
it has poorly predicted the human response to treatment with prospective anti-glioma 
therapies. The discrepancy between the success of preclinical studies and subsequent 
uniform failure of these therapies in large-scale phase III human clinical trials likely stems 
from the limited capacity of the murine model of glioma to fully approximate the intricate 
complexity of human disease.6
Human MGs are highly heterogeneous tumors, arising and continuously evolving in 
response to selective pressures within each unique tumor microenvironment (TME), 
including endogenous antitumor immune responses. A hallmark adaptation of human MG is 
the induction of a profoundly immunosuppressive environment that cripples naturally 
generated antitumor immune responses and limits the effectiveness of immunotherapies.7,8 
A critical component of tumor development and progression, is the complex interactions 
between tumor cells and the host immune system. This critical component is poorly modeled 
by the xenograft murine tumors that are established in immunodeficient host.
Dogs are known to spontaneously develop brain tumors with similar clinical and 
histopathological features to human disease.9 In particular, brachycephalic breeds like 
Boxers, English Bulldogs, and Boston Terriers are disproportionately prone to developing 
malignant gliomas.10,11 Spontaneously arising in genetically diverse and immunocompetent 
populations, canine gliomas may more accurately model the complexity of human disease, 
introducing the possibility of using canine studies to bridge the translational gap that 
currently exists between preclinical murine studies and human clinical trials. The larger dog 
brain size is also conducive to imaging studies monitoring disease progression and permits 
surgical tumor resection, allowing evaluation of treatment regimens more representative of 
those employed in human patients. Some groups have used a canine model of glioma for 
testing various treatment and drug delivery strategies12–14 highlighting the translational 
importance of this model.
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In order to integrate this model into the current anti-glioma therapy development pipeline, 
canine glioma must be thoroughly studied and defined in comparison to human disease. 
There have been various studies categorizing genetic changes specific to canine gliomas;
15,16
 for a comprehensive review on this topic, please refer to the paper by Bentley et al.6 
However, the interactions between the canine immune system and glioma tumors, 
systemically as well as within the tumor microenvironment, have not been described. Here, 
we further evaluate and characterize the immunologic and genetic expression profiles of 
spontaneous canine glioma, providing a foundation for future immunotherapy studies.
MATERIALS AND METHODS
Canine Patients
Canine tumor and normal brain tissue samples were collected at Purdue University IACUC 
protocol # 1404001056. The dogs were aged 3.0 to 9.6 years (median 6.7 years) and all were 
brachycephalic, except for two normal controls (Table 1). Of the 10 canine tumor samples, 7 
were collected during surgery and 3 were collected during necropsy. Normal brain tissue 
was collected from dogs euthanized for unrelated reasons. Samples were immediately flash-
frozen in liquid nitrogen and transferred to a −80° C freezer, with additional tissue placed in 
formalin. Tumor biopsy specimens submitted in formalin were used for histologic 
classification and grading.17
Immunohistochemistry
Gliomas were classified on the basis of hematoxylin and eosin-stained (H&E) sections and 
immunohistochemistry for glial fibrillary acidic protein (GFAP) and Olig2. A rabbit 
polyclonal antibody to recombinant mouse Olig2 (AB9610, EMD Millipore, Billerica, MA) 
was used for Olig2 immunohistochemistry as previously described.18 Normal astrocytes and 
oligodendrocytes in non-neoplastic canine cerebrum were used as positive controls for 
GFAP and Olig2, respectively.
RNA in Situ Hybridization
Detection of CD4, CD8, FoxP3, PD-1, PD-L1 and CTLA-4 mRNA expression in canine 
tumor samples was performed with RNA in situ hybridization using an RNAscope Multiplex 
Fluorescent Reagent Kit v2 (Cat. No. 323100, ACD). 4 µm sections of tissue were 
deparaffinized by twice incubating tissue slides in xylene for 5 minutes followed by twice 
incubation in 100% EtOH for 2 minutes. After slides were air-dried for 5 minutes, they were 
treated with 5–8 drops of RNAscope Hydrogen Peroxide, incubated for 10 minutes at room 
temperature, and washed twice in fresh distilled water. Afterwards, slides were submerged in 
a beaker containing RNAscope 1× Target Retrieval Reagents at temperatures between 98–
102°C for 15 minutes and washed with distilled water. A hydrophobic barrier was drawn 
around the tumor sample on the slide using an Immedge hydrophobic barrier pen (Cat. No. 
H4000, Vector Laboratories). Each slide was treated with 5 drops of RNAscope Protease 
Plus and incubated in the ACD HybEZ Oven at 40° for 30 minutes.
Target probes were designed using custom software as described previously.19 GenBank 
accession numbers and probe regions are as follows: CD4 (GenBank NM_001003252.1; 
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nucleotides 420–1373), CD8a (GenBank NM_001002935.2; nucleotides 41–900), FoxP3 
(GenBank NM_001168461.1; nucleotides 427–1382), PDCD1 (PD-1) (GenBank 
NM_001314097.1; nucleotides 75–756), CD274 (PD-L1) (GenBank NM_001291972.1; 
nucleotides 283–1237), and CTLA-4 (GenBank NM_001003106.1; nucleotides 689–1761). 
Probes were mixed and slides were stained according to manufacturer’s (ACD) instructions. 
Fluorophores used were TSA Plus fluorescein (Cat. No. NEL741001KT, PerkinElmer), TSA 
Plus Cyanine 3 (Cat. No. NEL744001KT, PerkinElmer) and TSA Plus Cyanine 5 (Cat. No. 
NEL745001KT, PerkinElmer). Slides were counterstained with DAPI and treated with 
Prolong Gold antifade mounting medium (Cat. No. P36930, Life Technologies). Images 
were captured using a confocal microscope (Olympus Fluoview FV1200) at 20× and 60× 
magnification. Fluorescent dots present on images captured at 60× magnification were 
counted to estimate mRNA expression in each slide sample.
Flowcytometry
Leukocytes were isolated from samples of canine brain tissue and peripheral blood using a 
previously established and published protocol20–22 and single cell suspension was created. 
Cells were stained with anti-canine CD3 (Serotec, NC0522562) conjugated with anti-mouse 
IgG DyLight 549 (BioRad, STAR117D549GA), anti-canine CD4 PE/Cy7 (eBioscience, 
25-5040-42), anti-canine CD8a eFluor 450 (eBioscience, 48-5080-42), anti-mouse/rat FoxP3 
APC (eBioscience, 17-5773-82), anti-human CD152-FITC (MyBioSource.com, 
MBS666569), antihuman PD-1 biotinylated antibody (R&D Systems, BAF1086) conjugated 
with streptavidin FITC (eBioscience, 11-4317-87), anti-canine CD45 eFluor 450 
(eBioscience, 48-5450-42), anticanine CD11c (BioRad, MCA17785) conjugated with anti-
mouse IgG FITC (BioRad, STAR117F), anti-human CD123 PE (eBioscience, 12-1239-41), 
anti-human CD83 APC (MACS, 130-098-889), and anti-human PD-L1 (CD274) PE/Cy7 
(BD Bioscience, BDB558017). Cells were analyzed by Flowcytometry, using a BD 
LSRFOrtessa X-20 cell analyzer, and data was analyzed with FlowJo V.10.2 software.
RNA extraction
Total RNA was purified from 25 mg brain tissue samples from 2 healthy and 4 glioma-
bearing canines using a Qiagen RNeasy Mini Kit (74106), according to manufacturer’s 
instructions. A NanoDrop ND-1000 spectrophotometer was used to determine sample 
concentration and RNA quality. RNA integrity was assessed with standard denaturing 
agarose gel electrophoresis. Stranded total RNA library preparations were prepared using the 
Illumina TruSeq mRNA Library Prep Kit single index.
Screening for differentially expressed genes
A comparison of gene expression in canine glioma and healthy brain tissue was performed 
using package edge R of R.23 Volcano plot filtering, with screening thresholds of a false 
discovery rate (FDR) < 0.01 and fold change (FC) >2, was used to identify differentially 
expressed genes (DEG).
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Functional enrichment analysis
Pathway analysis was performed to determine the significant biological pathways influenced 
by previously identified DEGs. DEGs were clustered into three groups according to the 
relative changes in expression between glioma and healthy tissue. Biological functional 
analysis was performed using gene ontology (GO) and the latest Kyoto Encyclopedia of 
Genes and Genomes (KEGG) databases through the Database for Annotation, Visualization, 
and Integrated Discovery (DAVID).24,25 A cutoff of FDR of <0.05 was set for selected GO 
and KEGG terms enriched in groups of DEGs.
Statistical methods
The expression of mRNAs between canine glioma and healthy brain tissues was compared 
using a paired t-test (p-value of <0.05 was considered statistically significant). Fisher’s exact 
test was used to select significant pathways (p <0.05) in pathway analysis. FDRs were 
calculated from Benjamini Hochberg FDR to correct p-values. All other data are presented 
as Mean ± SEM. Comparisons between two groups were conducted using Student’s t-test or 
Mann Whitney test as appropriate, and differences between more than two groups were 
assessed using ANOVA with Tukey’s post-hoc test. All analyses were conducted using 
GraphPad Prism version 4.0 (GraphPad Software, Inc.). All reported p-values were two 
sided and were considered to be statistically significant at * p<0.05, **p<0.01, ***p<0.001.
RESULTS
Canine glioma histology
Tumors were classified using microscopic features on H&E and Olig2 and GFAP 
immunohistochemistry and graded according to current canine tumor classification 
guidelines.12 Histologic analysis of canine glioma tissue samples (n=10) demonstrated 
features consistent with oligodendroglioma, nine of which were grade III anaplastic 
oligodendrogliomas (Fig. 1). These findings are consistent with prior data showing that, in 
contrast to the grade II oligodendrogliomas more commonly seen in humans, canine 
oligodendrogliomas tend to be anaplastic grade III tumors.6 Histopathological features 
including frequent mitotic figures, microvascular proliferation, and the presence of necrosis 
were used to recognize these grade III anaplastic tumors. Neoplastic cells were identified 
based on histologic features and by excluding normal cells such as neurons, endothelial cells 
and glia, and the percentage of neoplastic cells positive for each of Olig2 and GFAP was 
counted manually. All oligodendrogliomas exhibited strong Olig2 nuclear immunoreactivity 
(85% – 100% of neoplastic cells) and stained negative for GFAP. The grade III 
oligodendrogliomas were infiltrative, poorly demarcated from adjacent neuroparenchyma, 
and formed microvascular proliferations around foci of necrosis. Neoplastic cells had 
variable nuclear diameters and chromatin content with occasional mitotic figures.
Immune cell infiltrations in canine glioma
RNA in situ hybridization demonstrated the presence of CD4+ (20.375/high power field +/
− 4.705), CD8+ (52.375/high power field +/−18.114), and CD4+FoxP3+ regulatory (Treg) 
T-cells (11.625/high power field +/− 3.106) within canine glioma tissue (Fig. 2A). These 
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findings were confirmed in fresh canine glioma and normal brain tissue, with flow cytometry 
showing intratumoral infiltration with CD4+ (5.43% +/− 1.27), CD8+ (50.83% +/− 3.67), 
and regulatory (16.76% +/− 5.10) T-cells. We also found a significantly higher frequency of 
CD8+ (p < 0.0014) and Treg (p < 0.0465) cell infiltration in canine glioma compared to 
healthy canine brain (Fig. 2B).
Glioma-bearing canines also possessed significantly greater proportions of circulating Treg 
cells (0.737% +/− 0.073 normal vs. 1.972% +/− 0.324 glioma; p<0.03) (Fig. 2C).
Immune checkpoint expression in healthy and glioma-bearing canines
We evaluated the presence of cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed 
cell death-1 (PD-1) and its ligand, PD-L1 in the glioma microenvironment using RNA in situ 
hybridization. We observed prominent PD-L1 staining in canine glioma tissue (173.875/high 
power field +/− 76.170) and the presence of CTLA-4 (23.00/high power field +/− 6.982) and 
PD-1 (14.875/high power field +/− 3.340) expressing cells (Fig. 3A).
Flow cytometric analysis was performed on peripheral blood lymphocytes to further define 
immune checkpoint expression. Compared to healthy controls, there was significantly 
greater PD-1 expression on CD4+ (4.157% +/− 1.536 normal vs. 9.052% +/− 0.826 glioma; 
p<0.01) and CD8+ (0.543% +/− 0.097 normal vs. 2.408% +/− 0.225 glioma; p<0.0009) T-
cells from glioma-bearing canines (Fig. 3B). Tumor-bearing animals possessed a 
significantly greater proportion of CTLA-4-expressing CD8+ T-cells (15.10% +/− 7.554 
normal vs. 44.52% +/− 6.951 glioma; p<0.03) and relatively more CTLA-4-expressing 
CD4+ T-cells, although this difference did not reach statistical significance (Fig. 3C). We 
also observed fewer CTLA-4-expressing peripheral blood Treg cells in glioma-bearing dogs 
(7.543% +/− 4.147 normal vs. 0.1733% +/− 0.1733 glioma; p<0.03). The average peripheral 
blood Treg PD-1 expression did not differ between our two canine populations.
Dendritic cell populations in canine glioma
Using flow cytometry, we compared the presence of plasmacytoid (pDC) and myeloid 
(mDC) dendritic cells in the brain and peripheral blood of glioma-bearing and healthy dogs. 
In comparison to healthy canine brain, canine glioma tissue contained a significantly greater 
presence of pDCs (0.0650% +/− 0.011 normal vs. 7.917% +/− 1.204 glioma; p<0.0001) and 
fewer mDCs (4.983% +/− 0.2845 normal vs. 2.833% +/− 0.6805 glioma; p<0.0154) (Fig 
4A). There was also a significant increase in circulating pDCs in glioma-bearing canines 
(10.43% +/− 6.385 normal vs. 54.02% +/− 7.217 glioma; p<0.006) and a trend towards 
increased mDC presence, though this was not statistically significant (p<0.16) (Fig 4B).
Similar to human patients,26 PD-L1 expression was detected on peripheral blood mDCs and 
pDCs in tumor-bearing and healthy canines, though there were no significant differences in 
expression frequency or density on either DC subtype (Fig 4C).
Canine expression of genes associated with human glioma
Gene expression in canine glioma and normal canine brain was evaluated with mRNA 
sequencing. Volcano plot analysis identified 1450 differentially expressed genes (DEGs) 
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between these populations (Fig. 5A). Of these DEGs, 626 were upregulated (red dots) and 
824 were downregulated (blue dots) in glioma tissue relative to healthy controls. We selected 
a subset of genes associated with human glioma and evaluated their expression in our canine 
populations; their relative expression, on a logarithmic scale, is depicted in (Fig 5B).
DEG analyses revealed that similar to human MG, canine glioma possess genetic mutations 
impacting the retinoblastoma (RB), TP53, and receptor tyrosine kinase (RTK)/PI3K 
pathways. Canine gliomas also exhibited amplification of neurodevelopmental genes, 
OLIG2, NKX2-2, and SOX2, commonly overexpressed in human astrocytomas and 
oligodendrogliomas. Other genes upregulated in tumors of both species were CCNB1, a 
mitosis-related cyclin, and KIF11, a mitotic kinesin promoting tumor invasion and 
proliferation.27 Additionally, increased expression of DNA methyltransferase DNMT1 in 
both species suggests the importance of epigenetic changes in oncogenesis.28,29 In human 
GBM, overexpression of DNMT1 has been correlated with reduced MGMT expression30 
and repression of the p53 pathway.31
We also identified several genes with canine patterns of expression opposite those seen in 
human glioma. PAK1, which promotes Akt signaling, angiogenesis, and GBM 
invasiveness32 and MAPK12, which represses cell proliferation33 are two kinases commonly 
upregulated in human GBM, that were downregulated in our canine oligodendroglioma.
Functional pathway analysis of canine DEGs
DEGs were categorized into one of three groups based on relative changes in expression 
between healthy tissue and glioma. Groups C1 and C2 contained genes overexpressed in 
canine glioma. Genes expressed only in glioma tissue were assigned to C1, and genes 
expressed in both populations were assigned to C2. C3 contained the 824 genes that were 
downregulated in glioma as compared to healthy tissue. A depiction of this hierarchal 
clustering is shown in (Fig 5C). A list of all the genes and involved pathways is provided as 
part of the supplementary file.
Gene ontology and KEGG pathway enrichment analyses were performed on clustered DEGs 
to categorize them within biologically relevant functions or pathways (Fig. 5D). A 
comprehensive list of all genes affected is provided in the supplementary data. DEGs in 
clusters C1 and C2 were evaluated with both methods. Common pathways identified as 
impacted by genes overexpressed in canine glioma include those enhancing transcriptional 
activity, cell cycle progression, and angiogenesis. Others promoted TGF-beta signaling and 
epithelial to mesenchymal transition, both of which have strong implications in tumor 
development. There was also a prevalent upregulation of genes related to microRNAs 
previously associated with cancer, further highlighting the importance of epigenetic changes 
in oncogenesis. Analysis of the C3 cluster showed that genes downregulated in glioma 
includes those supporting neuronal maintenance and function. Healthy brain tissue, 
primarily composed of neurons, would be expected to have greater expression of genes 
related to normal neuronal function as compared to gliomas, which are principally formed of 
malignant glial cells. The relatively reduced expression of neuron-related genes in canine 
glioma tissue clearly reflects the different primary cell populations within these samples and 
supports the overall validity of this analysis.
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DISCUSSION
Human MGs are highly aggressive, uniformly fatal brain tumors critically in need of more 
effective treatment strategies. One of the factors underlying the persistent difficulties to 
develop survival-prolonging treatments is the lack of a preclinical model capable of reliably 
predicting treatment efficacy in human patients. Although essential for studying basic 
mechanisms driving glioma progression, murine tumor models fail to fully encompass the 
complexity of human disease. Utilization of a higher-level spontaneous animal model better 
approximating human disease is expected to more accurately predict the efficacy of 
prospective anti-glioma treatments following murine studies, thereby improving the 
possibility of successful transition to human clinical trials.6,34 In contrast to mice, dogs 
spontaneously develop MGs with similar histopathologic features, radiologic presentations, 
and clinical responses to conventional antitumor therapies as human disease.35,36 In this 
study, we for the first time characterize the immunologic landscape of canine glioma and 
further evaluate its potential to approximate human disease.
Given the importance of host immune responses to human MG progression as well as 
response to treatment, especially immunotherapeutic treatment strategies, it is imperative 
that the influence of these complex interactions be accounted for at some stage of preclinical 
testing. A hallmark of human GBM is the induction of an immunosuppressive state that 
reduces the effectiveness of endogenous antitumor immune responses, and consequently the 
therapeutic potential of immunotherapies. In this study, we demonstrate that canine tumors 
possess many of the same immunologic characteristics as their human counterparts. In 
addition to establishing the presence of tumor infiltrating lymphocytes (TILs) in canine 
glioma, we show that pDCs are the major antigen-presenting cell in the canine glioma 
microenvironment. Furthermore, we characterize the expression of immune checkpoints 
within the brain tissue and peripheral blood of healthy and glioma-bearing canines. Given 
the similarities we have identified between canine and human glioma immune profiles, we 
predict that glioma-bearing dogs will respond similarly to treatment, particularly with 
immunotherapies, as human patients.
Human gliomas contain prominent CD4+ and CD8+ T-cell infiltrates.37,38 Similar to the 
trend we observed in glioma-bearing dogs, the majority of T-cells within human glioma are 
CD8+ T-cells, the primary effectors of host antitumor immune responses.37 Also 
characteristic of human MG is an intratumoral accumulation of immunosuppressive 
regulatory T-cells. Treg cells have a strong inhibitory impact on dendritic cell maturation and 
the activation, proliferation, and function of CD4+ and CD8+ lymphocytes,26 and their 
intratumoral accumulation is associated with a poor prognosis.39,40 In addition to 
intratumoral Treg cell infiltrates, human MG patients have been shown to possess elevated 
levels of circulating Treg cells (8.56%) as compared to healthy volunteers (0.48%).41 We 
observed an accumulation of Treg cells within the tumors and peripheral blood of glioma-
bearing canines as compared to healthy controls, supporting the assertion that Treg cells 
contribute similarly to glioma-induced immunosuppression in canines.
In addition to accumulating inhibitory leukocytes, human MGs suppress antitumor responses 
through enhanced activation of CTLA-4 and PD-1 immune checkpoints, endogenous 
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negative regulators of T-cell activity. Binding of PD-1 on activated T-cells to PD-L1, often 
overexpressed by tumor cells, inhibits T-cell proliferation and cytokine release, leading to T-
cell anergy, apoptosis, or Treg cell development. Activation of CTLA-4, induced on naïve T-
cells, prevents initial T-cell activation. Consistent with a recent observation that 88% of 
human GBM express PD-L1,37 we found elevated PD-L1 staining in all canine glioma 
samples. Not expressed by healthy human tissues, elevated PD-L1 expression in canine 
tumors indicates that canine gliomas employ similar methods of immunosuppression as 
human tumors. Increased expression of CTLA-4 and PD-1 receptors, characteristically seen 
on intratumoral37,39 and peripheral blood38,42 lymphocytes of human MG patients, was 
observed in the lymphocytes of our glioma-bearing canines. In comparing immune 
checkpoint expression on different lymphocyte populations we did find a relatively reduced 
expression of CTLA-4 on canine glioma-bearing Tregs, which is in contrast to reports of 
elevated Treg CTLA-4 expression in human MG patients (76.8%) compared to healthy 
controls (50%).41 This discrepancy could indicate a different role for, or timing of, 
immunosuppression via this pathway in human and canine glioma.
Although MGs are highly genetically diverse, there are several pathways dysregulated in the 
majority of human tumors, such as PI3K, RAS, etc. In a recent study of core genetic 
mutations in human GBM, 87%, 78%, and 88% of analyzed samples harbored somatic 
mutations of the RB, TP53, and RTK/PI3K signaling pathways, respectively.43 One of the 
most common mutations affecting the RB pathway in human GBM is amplification of 
CDK4 (14%), a cyclin-dependent kinase promoting cell cycle progression.43 Upregulated in 
our canine tumor samples, amplification of CDK4 is also associated with progression of 
human anaplastic oligodendrogliomas.44 Altered p53 pathway signaling in human GBM 
occurs through direct mutation of p53 (35%), though also occurs via ARF deletions (49%) 
and/or amplification of MDM2 (14%) or MDM4 (7%).43 Direct P53 inactivation is less 
commonly seen in human oligodendrogliomas,44 and TP53 mRNA expression was relatively 
upregulated in our canine oligodendroglioma, consistent with historical evaluations.16 This 
overexpression may be related to additional functions of p53, although these tumors may 
possess other mutations allowing escape of p53-dependent growth control. One such 
mutation seen in human tumors and our canine glioma is overexpression of OLIG2, a 
neurodevelopmental transcription factor. OLIG2 directly represses the activity of cell cycle 
inhibitor p21 (CDKN1A)45 and antagonizes p53 function by impacting post-translational 
protein modification.46 Other neurodevelopmental transcription factors overexpressed in 
human oligodendrogliomas and GBM subtypes as well as our canine glioma are NKX2-247 
and SOX2.48 Also commonly observed in human GBM are activating mutations of the 
growth-promoting receptors EGFR (57%) and PDGFRA (10%).48,49 PDGFRA 
amplification also occurs in highly anaplastic human oligodendrogliomas displaying features 
of WHO grade IV malignancies44 and was observed in our canine tumors as well. Other 
genes associated with the PI3K pathway in humans that were not differentially regulated in 
our canine populations are ERBB2, PTEN, and NF1.43 PTEN loss is less common in human 
anaplastic oligodendrogliomas44 and rarely occurs in canine gliomas.50 These results imply 
that human and canine gliomas arise from dysregulation of common pathways and suggest 
that they may respond similarly to treatment. Future analyses must assess downstream 
signaling and the influence of epigenetic mutations like MGMT methylation on disease 
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progression and treatment response. Studies with larger sample sizes may be useful in 
identifying less commonly mutated pathways and may lead to the identification of novel 
molecularly defined subclasses with relevant clinical applications, as has been done in 
human disease.
This study has identified clear commonalities between the immunologic response profiles 
and genetic mutations observed in human and canine gliomas. Arising from commonly 
dysregulated cellular pathways and displaying similar interactions with host immune 
systems, spontaneous canine glioma possess many of the same complex characteristics 
found in human disease that may render them a more appropriate model to predict 
therapeutic efficacy of anti-glioma treatments, particularly immunotherapies. Incorporation 
of spontaneous canine glioma as a transitional model for testing emerging anti-glioma 
treatments proven successful in preclinical murine studies has potential to significantly 
improve the success of subsequent human clinical trials, leading to the development of more 
effective treatments for MG in both human and dogs.
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IMPORTANCE OF THE STUDY
MGs are highly infiltrative, heterogeneous, and treatment-resistant tumors. Underlying 
the failure of promising pre-clinical treatment strategies to successfully treat human 
disease is the lack of ability of the artificial mouse model to fully capture the complexity 
of human MG and therefore poor capacity to predict adverse effect and therapeutic 
success in human patients. Canine brain tumors that spontaneously develop in 
immunocompetent hosts and share similar environmental stressors as human tumors 
provide an attractive intermediate platform for evaluating the effectiveness of anti-glioma 
treatment strategies, especially immunotherapies, proven successful in preclinical murine 
studies. To substantiate the validity of this model, we for the first time describe the 
immunologic landscape and gene expression profiles of spontaneous canine glioma. 
Understanding the immune responses generated against canine glioma will help better 
integrate this model into the anti-glioma therapy development process.
Filley et al. Page 14
J Neurooncol. Author manuscript; available in PMC 2019 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Histology of Canine Glioma Samples
A) Grade III oligodendroglioma (upper right) invades adjacent cerebral parenchyma. Scale 
bar, 100 µm. (B) Microvascular proliferation is prominent around a necrotic focus (top) in 
Grade III oligodendroglioma. Scale bar, 100 µm. Upper inset depicts Olig2 
immunohistochemistry with nuclear labeling in neoplastic cells but no Olig2 expression by 
cells of the microvascular proliferation (asterisks). Lower inset depicts processes of a few 
GFAP–positive astrocytes (arrows), but the neoplastic cells are negative. (C) Most neoplastic 
cells in this Grade III oligodendroglioma have a hyperchromatic nucleus with occasional 
mitotic figures (arrow) and a clear perinuclear ‘halo’, an artifact of delayed fixation. Scale 
bar, 50 µm. (D) Neoplastic cells in this Grade III oligodendroglioma have a larger 
hypochromatic nucleus with occasional mitotic figures (arrow) and pale eosinophilic 
cytoplasm with indistinct cell borders. Scale bar, 50 µm. (n = 10)
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Figure 2. T-cell Presence in Canine Glioma and Peripheral Blood
A) RNA in situ hybridization of tumor samples stained with DAPI and three RNA probe 
conjugated markers, cyanine 3 [CD4], cyanine 5 [CD8] and fluorescein [FoxP3]. Yellow 
markers, a combination of green [FoxP3] and red [CD4], are indicative of Treg cells. (a) 
Staining for CD4, CD8, and FoxP3 shown at 20× magnification. Scale bar, 50 µm. (b) 
Staining for CD4 at 60×. Scale bar, 20 µm. (c) Staining for CD8 at 60×. Scale bar, 20 µm. 
(d) Staining for Treg (CD4 and FoxP3) shown at 60× magnification. Scale bar, 20 µm. (e) A 
scatter plot showing the number of CD4, CD8 and Treg markers counted on slide samples at 
60× magnification. (n = 8) B) Gating strategy for CD4+, CD8+ and CD4+FoxP3+ Treg cells 
in normal brain tissue and high-grade canine glioma. The bar diagram represents the 
percentage of CD4+, CD8+, and CD4+FoxP3+ T cells in normal brain tissue (n = 3) vs. high 
grade glioma (n = 6). C) CD8+, CD4+ and CD4+Foxp3+ T cells in the peripheral blood of 
normal dogs compared to dogs with glioma.
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Figure 3. Immune Checkpoint Markers on Tumor-Infiltrating and Circulating Immune Cells
A) RNA in situ hybridization of tumor samples stained with DAPI and three RNA probe 
conjugated markers, cyanine 3 [CTLA-4], cyanine 5 [PD-L1] and fluorescein [PD-1]. (a) 
Staining for CTLA-4, PD-L1, and PD-1 shown at 20× magnification. Scale bar, 50 µm. (b) 
Staining for CTLA-4, PD-L1, and PD-1 shown at 60× magnification. Scale bar, 20 µm. (c) 
Staining for CTLA-4 at 60×. Scale bar, 20 µm. (d) Staining for PD-L1 at 60×. Scale bar, 20 
µm. (e) Staining for PD-1 at 60×. Scale bar, 20 µm. (f) Scatter plot showing number of 
CTLA-4, PD-L1 and PD-1 markers counted on slide samples at 60× magnification. (n = 8) 
B) Gating strategy for analyzing PD-1 expression on CD4+, CD8+ and CD4+FoxP3+ T cells 
in peripheral blood of normal dogs (n = 3) vs. dogs with glioma (n = 6) and scatter plots 
representing the percentage of T-cells expressing PD-1. C) Gating strategy for analyzing 
CTLA-4 expression on CD4+, CD8+ and CD4+FoxP3+ T cells in peripheral blood of normal 
(n = 3) and glioma-bearing dogs (n = 6) and scatter plots representing the percentage of T-
cells expressing CTLA-4.
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Figure 4. pDC and mDC Populations in Brain Tissue and Peripheral Blood of Normal and 
Glioma-Bearing Canine Patients
A) Gating strategy for analyzing pDCs and mDCs from normal brain tissue (n = 6) and 
canine glioma (n = 6). Scatter plots representing the percentage of pDCs and mDCs B) 
Gating strategy for analyzing pDCs and mDCs in the peripheral blood of normal (n = 3) and 
glioma-bearing dogs (n = 6). Scatter plots representing the percentage of pDCs and mDCs 
C) Gating strategy for analyzing PD-L1 expression on pDCs and mDCs in peripheral blood 
of normal dogs (n = 3) vs. dogs with glioma (n = 6) and scatter plots representing the 
percentage of DCs expressing PD-L1.
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Figure 5. DEG Expression Patterns and Corresponding Biological Functions/Pathways
A) Volcano Plot showing cutoffs of FDR-adjusted P-value and FC for all genes and DEGs. 
B) Gene expression in normal and glioma canine brain tissue of a set of genes associated 
with human glioma. C) Heat Map of Gene Expression for 3 Groups of DEGs D) 
Significantly over-represented KEGG pathways and GO functions in 3 groups of DEGs 
identified (n = 2 normal; 4 glioma).
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Table 1
Table of glioma histological type/normal control and dog breed
Canine Breed Age Diagnosis
1 Dogue de Bordeaux 4.5 yr. oligodendroglioma III
2 Boxer 7.0 yr. oligodendroglioma III
3 Boxer 6.3 yr. oligodendroglioma III
4 Boston terrier 9.6 yr. oligodendroglioma III
5 Boston terrier 8.8 yr. oligodendroglioma II
6 English Bulldog 7.2 yr. oligodendroglioma III
7 Boxer 7.8 yr. oligodendroglioma III
8 Boxer 5.8 yr. oligodendroglioma III
9 Mixed Breed 5.8 yr. oligodendroglioma III
10 Boxer 3.0 yr. oligodendroglioma III
11 Boxer 8.2 yr. Normal Brain
12 Chesapeake Bay Retriever 3.7 yr. Normal Brain
13 Siberian Husky 2.0 yr. Normal Brain
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